Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

766 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.
Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell'Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d'Amati G. Fusco N, et al. Among authors: fernandes b. Crit Rev Oncol Hematol. 2023 Oct;190:104103. doi: 10.1016/j.critrevonc.2023.104103. Epub 2023 Aug 16. Crit Rev Oncol Hematol. 2023. PMID: 37595344 Review.
Real-world use of multigene signatures in early breast cancer: differences to clinical trials.
Licata L, De Sanctis R, Vingiani A, Cosentini D, Iorfida M, Caremoli ER, Sassi I, Fernandes B, Gianatti A, Guerini-Rocco E, Zambelli C, Munzone E, Simoncini EL, Tondini C, Gentilini OD, Zambelli A, Pruneri G, Bianchini G. Licata L, et al. Among authors: fernandes b. Breast Cancer Res Treat. 2024 May;205(1):39-48. doi: 10.1007/s10549-023-07227-0. Epub 2024 Jan 24. Breast Cancer Res Treat. 2024. PMID: 38265569 Free PMC article.
18 F-FET PET/CT in Calcifying Pseudoneoplasm of the Neuraxis : First Case.
Aricò D, Giacoppo G, Bambaci M, Marino L, Girlando A, Sortino G, Leone G, Fernandes B, Alì M, Evangelista L, Romano A. Aricò D, et al. Among authors: fernandes b. Clin Nucl Med. 2024 Jun 1;49(6):e272-e273. doi: 10.1097/RLU.0000000000005197. Epub 2024 Mar 25. Clin Nucl Med. 2024. PMID: 38537205
Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience.
Torrisi R, Garcia-Etienne CA, Losurdo A, Morenghi E, Di Tommaso L, Gatzemeier W, Sagona A, Fernandes B, Rossetti C, Eboli M, Rubino A, Barbieri E, Andreoli C, Orefice S, Gandini C, Rota S, Zuradelli M, Masci G, Santoro A, Tinterri C. Torrisi R, et al. Among authors: fernandes b. Breast. 2013 Aug;22(4):419-24. doi: 10.1016/j.breast.2013.03.013. Epub 2013 May 3. Breast. 2013. PMID: 23643803
Digital Pathology During the COVID-19 Outbreak in Italy: Survey Study.
Giaretto S, Renne SL, Rahal D, Bossi P, Colombo P, Spaggiari P, Manara S, Sollai M, Fiamengo B, Brambilla T, Fernandes B, Rao S, Elamin A, Valeri M, De Carlo C, Belsito V, Lancellotti C, Cieri M, Cagini A, Terracciano L, Roncalli M, Di Tommaso L. Giaretto S, et al. Among authors: fernandes b. J Med Internet Res. 2021 Feb 22;23(2):e24266. doi: 10.2196/24266. J Med Internet Res. 2021. PMID: 33503002 Free PMC article.
Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients.
Gentile D, Sagona A, De Carlo C, Fernandes B, Barbieri E, Di Maria Grimaldi S, Jacobs F, Vatteroni G, Scardina L, Biondi E, Vinci V, Trimboli RM, Bernardi D, Tinterri C. Gentile D, et al. Among authors: fernandes b. Breast. 2023 Jun;69:323-329. doi: 10.1016/j.breast.2023.03.016. Epub 2023 Mar 28. Breast. 2023. PMID: 37001289 Free PMC article.
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
Miglietta F, Ragazzi M, Fernandes B, Griguolo G, Massa D, Girardi F, Bottosso M, Bisagni A, Zarrilli G, Porra F, Iannaccone D, Dore L, Gaudio M, Santandrea G, Fassan M, Lo Mele M, De Sanctis R, Zambelli A, Bisagni G, Guarneri V, Dieci MV. Miglietta F, et al. Among authors: fernandes b. Clin Cancer Res. 2023 Sep 1;29(17):3429-3437. doi: 10.1158/1078-0432.CCR-23-0480. Clin Cancer Res. 2023. PMID: 37417941 Free PMC article.
766 results